Healthcare >> CEO Interviews >> October 14, 2002
DR. RON COHEN is President, Chief Executive Officer, and Founder of
Acorda Therapeutics, Inc., a biotechnology company developing therapies
for spinal cord injury, multiple sclerosis and other disorders of the
central nervous system. Dr. Cohen previously was a Principal in the
startup of Advanced Tissue Sciences, Inc., a biotechnology company
engaged in the growth of human organ tissues for transplantation uses.
Dr. Cohen received his BA degree with honors in Psychology from
Princeton University and his MD from the Columbia College of Physicians
& Surgeons. He completed a residency in Internal Medicine at the
University of Virginia Medical Center, and is Board Certified in
Internal Medicine. Dr. Cohen serves on the Boards of Directors of
Ceregene, Inc., and the New York Biotechnology Association. He also
serves on the Advisory Editorial Board of BioPeople magazine, and as a
member of the Columbia-Presbyterian Health Sciences Council. Profile
TWST: Will you give us a brief history and overview of AcordaTherapeutics?
Dr. Cohen: I worked for about a year and a half on diligence setting it
up beginning in the fall of 1993. The